DEF: Charles River Labs Prepares for Leadership Shift, New Incentive Plan
Sentiment:
Proxy Statement
Charles River Laboratories International, Inc. announces a leadership transition with CEO James C. Foster's retirement, the appointment of Birgit Girshick as his successor, and proposals for a new long-term incentive plan and director elections at its 2026 Annual Meeting.
Worse than expectedGAAP diluted loss per share of $(2.91) in fiscal year 2025, a significant decline from GAAP diluted earnings per share of $0.20 in 2024.The GAAP net income available to common shareholders was a loss of $(144,338,000) in 2025, compared to a gain of $10,297,000 in 2024.The primary driver for the GAAP loss was non-cash intangible asset and goodwill impairments totaling $376.0 million in Q4 2025.Revenue decreased by 0.9% and non-GAAP diluted EPS decreased by 0.4% in fiscal year 2025, indicating a challenging operating environment despite some positive operational metrics.
Summary
- Shareholders are invited to the 2026 Annual Meeting on May 5, 2026, to vote on the election of twelve directors, an advisory resolution on executive compensation, approval of the 2026 Long-Term Incentive Plan, and ratification of PricewaterhouseCoopers LLP as the independent auditor.
- James C. Foster will retire as CEO and Chair of the Board, effective May 5, 2026, and will remain a non-executive director.
- Birgit Girshick, current Chief Operating Officer, will be appointed Chief Executive Officer, effective May 5, 2026.
- Dr. Martin W. Mackay, the current Lead Independent Director, will become the Chair of the Board, separating the CEO and Chair roles.
- The company reported a 0.9% decrease in revenue and a GAAP diluted loss per share of $(2.91) for fiscal year 2025, a decrease from GAAP diluted earnings per share of $0.20 in 2024.
- Non-GAAP diluted earnings per share decreased by 0.4% in fiscal year 2025.
- Cash flow from operating activities increased by 0.4% to $737.6 million in fiscal year 2025.
- The Board recommends approval of the 2026 Long-Term Incentive Plan, authorizing up to 4,825,000 shares of common stock, to replace the 2018 Incentive Plan.
- The 2025 annual cash incentive awards resulted in a payout of 139% of target due to exceeding Revenue and Operating Income goals.
- The 2023 Performance Share Units (PSUs) paid out at 87.3% of target, reflecting above-target 2023 EPS performance but below-target relative Total Shareholder Return (rTSR).
- The company repurchased 2.1 million shares for $350.0 million in fiscal year 2025 and approved a new $1.0 billion stock repurchase authorization.
Sentiment
Score: 4
Explanation: StockSavvy.ai views this filing with caution due to the significant GAAP loss and revenue decline in 2025, primarily driven by non-cash impairments. While leadership transition and strategic initiatives are positive, the immediate financial results are concerning.
Positives
- Exceeded Revenue and Operating Income goals for fiscal year 2025, leading to a 139% payout for annual cash incentive awards.
- Cash flow from operating activities increased by 0.4% to $737.6 million in fiscal year 2025.
- Approved a new $1.0 billion stock repurchase authorization on October 29, 2025, demonstrating a commitment to returning value to shareholders.
- Successful mitigation of NHP supply challenges through enhanced safeguards, international diversification, and strategic acquisitions (K.F. (Cambodia) Ltd. in Jan 2026, Noveprim Group in 2023).
- Strong shareholder support (approximately 96%) for executive compensation at the 2025 Annual Meeting.
- Implementation of a leadership transition plan ensures continuity and strategic alignment with Birgit Girshick appointed as the new CEO and separation of CEO and Chair roles.
- The proposed 2026 Long-Term Incentive Plan includes features designed to protect shareholder interests, such as minimum vesting requirements for 95% of awards, a non-employee director compensation limit, and no single-trigger vesting on a change in control.
- The company's three-year average burn rate of 1.1% for equity awards demonstrates prudent share usage.
Negatives
- Revenue decreased by 0.9% in fiscal year 2025.
- GAAP diluted loss per share was $(2.91) in fiscal year 2025, a significant decrease from GAAP diluted earnings per share of $0.20 in 2024.
- Non-GAAP diluted earnings per share decreased by 0.4% in fiscal year 2025.
- The primary driver of the GAAP decrease in 2025 was non-cash intangible asset and goodwill impairments totaling $376.0 million ($211.0 million and $165.0 million, respectively) in the fourth quarter of 2025.
- The performance period for 2023 PSUs resulted in a payout of 87.3% of target, partly due to below-target relative Total Shareholder Return (rTSR).
- The company faces a continuously evolving market and challenging demand trends from biopharmaceutical clients, with revenue from both large biopharmaceutical and small and mid-sized biotechnology clients declining in fiscal year 2025 due to cautious R&D spending.
Risks
- Market Volatility and Demand Fluctuations: The biopharmaceutical market is continuously evolving, with demand from clients stabilizing but still facing challenges, leading to decreased revenue from both large biopharmaceutical and small and mid-sized biotechnology clients in fiscal year 2025 due to cautious R&D spending.
- Supply Chain Challenges: Ongoing efforts are required to secure the supply chain and mitigate non-human primate (NHP) supply challenges, which have previously led to legal costs and inventory write-downs.
- Talent Attraction and Retention: Without approval of the new 2026 Long-Term Incentive Plan, the company would experience serious disruption of compensation programs and be compelled to increase the cash component of employee and director compensation, potentially leading to a significant competitive disadvantage in attracting and retaining key employees.
- Integration Risks: Strategic acquisitions and divestitures, while aimed at strengthening the portfolio, carry inherent integration risks and the potential for capital redeployment in other long-term growth opportunities.
- Operational Regulatory Matters: The Board oversees risks related to operational regulatory matters, such as quality control and data privacy.
- Information Security Risk: The Audit Committee oversees information security risk, including risks related to the utilization of artificial intelligence tools.
- Financial Reporting and Internal Controls: Risks associated with financial reporting and disclosures, and the system of internal controls, are overseen by the Audit Committee.
- Executive Compensation Clawback: Executive compensation is subject to recoupment in the event of an accounting restatement resulting from material noncompliance with financial reporting requirements.
Future Outlook
The company is actively positioning itself to leverage its leadership in non-clinical drug development and capitalize on market opportunities as the demand environment improves. This includes strengthening its scientific portfolio through strategic acquisitions, partnerships, internal investments, and divestments of non-core assets. The appointment of a new CEO and the proposed 2026 Long-Term Incentive Plan are designed to ensure long-term continuity, stability, and strategic alignment, supporting future growth and talent management.
Management Comments
- "You are cordially invited to attend the 2026 Annual Meeting of Shareholders of Charles River Laboratories International, Inc. to be held at 8:00 a.m. on Tuesday, May 5, 2026." James C. Foster, Chair, President and Chief Executive Officer.
- "Our Board of Directors recommends the approval of the proposals to elect each of the twelve directors, to approve the advisory vote on our executive compensation, to authorize the new equity incentive plan, and to ratify the selection of PricewaterhouseCoopers LLP." James C. Foster, Chair, President and Chief Executive Officer.
- "Whether you plan to attend the Annual Meeting or not, it is important that your shares are represented. Therefore, we urge you to complete, sign, date and return the enclosed proxy card promptly or use internet voting prior to the Annual Meeting." James C. Foster, Chair, President and Chief Executive Officer.
- "The Board believes that the Plan will help the Company continue to achieve our goals by keeping the incentive compensation program dynamic and competitive with that of other companies and ensuring that we may continue to attract and retain key employees who are expected to contribute to our success." Board of Directors regarding the 2026 Long-Term Incentive Plan.
- "Our financial performance in fiscal year 2025 demonstrated resilience and stability in a continuously evolving market." Management regarding 2025 performance.
- "We are actively positioning the Company to leverage our leadership position in non-clinical drug development and be able to capitalize on opportunities both in the marketplace and when the demand environment improves." Management on strategic direction.
Industry Context
StockSavvy.ai notes that Charles River Laboratories operates within the dynamic biopharmaceutical industry, which experienced stabilizing but challenging demand trends in fiscal year 2025, particularly due to cautious early-stage R&D spending from both large biopharmaceutical and small and mid-sized biotechnology clients. The company's strategic focus on outsourcing solutions, scientific capabilities, and global scale aligns with broader industry trends where clients increasingly rely on partners for operating efficiency and specialized expertise. The emphasis on new approach methodologies (NAMs) and digital transformation (Apollo platform) reflects an industry-wide push for innovation and efficiency in drug discovery and development. The leadership transition and new incentive plan are critical for maintaining competitiveness in a tight talent market, a common challenge across the life sciences sector.
Comparison to Industry Standards
- The company's executive compensation program, with 96% shareholder support in 2025, indicates strong alignment with investor expectations, potentially outperforming some peers facing "say-on-pay" challenges.
- The 2026 Long-Term Incentive Plan's features, such as minimum vesting requirements for 95% of awards and double-trigger vesting on change of control, align with leading corporate governance practices, potentially placing Charles River Laboratories ahead of some industry peers that may have less stringent equity award structures.
- The three-year average burn rate of 1.1% is a favorable indicator of responsible equity dilution compared to industry benchmarks, suggesting efficient use of stock for compensation.
- The fully-diluted overhang of 15.6% should be evaluated against industry averages for similar life science companies to determine its competitiveness and potential impact on shareholder value.
- The company's commitment to ESG principles, including GHG emission reduction goals approved by SBTi, positions it favorably against global benchmarks for corporate sustainability, potentially attracting ESG-focused investors.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Chief Executive Officer and Chair of the Board | James C. Foster | Birgit Girshick (CEO), Martin W. Mackay (Chair) | May 5, 2026 | Planned retirement of Mr. Foster and leadership transition plan. |
| Non-executive Director | NA | James C. Foster | May 5, 2026 | Transition from executive roles. |
| Chief Financial Officer | Flavia H. Pease | Michael G. Knell (Interim) | September 14, 2025 | Voluntary resignation of Ms. Pease. |
| Chief Financial Officer | Michael G. Knell (Interim) | Glenn Coleman | April 6, 2026 | Appointment of permanent successor. |
| Director | George E. Massaro | NA | May 20, 2025 | Chose not to stand for re-election. |
| Director | Richard F. Wallman | NA | May 20, 2025 | Chose not to stand for re-election. |
| Director | Robert Bertolini | NA | May 20, 2025 | Chose not to stand for re-election. |
| Director | Deborah T. Kochevar | NA | May 20, 2025 | Chose not to stand for re-election. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Board Leadership Structure | Separation of the Chair and CEO roles, with Dr. Martin W. Mackay becoming Chair and Ms. Birgit Girshick becoming CEO, effective May 5, 2026. This is intended to support risk management and allow the CEO to focus on operations. | May 5, 2026 | Enhances independent oversight and strategic focus by separating the top leadership roles, aligning with best governance practices. |
| Committee Structure | Creation of the New Approach Methodologies and Science (NAMS) Committee in 2025, combining the former Responsible Animal Use Committee and the Science and Technology Committee. | 2025 | Streamlines oversight of scientific innovation, responsible animal utilization, and emerging trends, reflecting evolving industry and ethical considerations. |
| Director Compensation Policy | Beginning May 2026, the annual base cash fee for non-employee directors will increase to $75,000, and the Chair of the Board will receive an additional annual fee of $175,000. Non-employee director equity grants will be 100% RSUs, eliminating stock options. | May 2026 | Aims to attract and retain qualified directors with competitive compensation, while shifting equity awards entirely to RSUs to better align with long-term value creation and reduce volatility exposure. |
| Equity Incentive Plan | Proposed 2026 Long-Term Incentive Plan (LTIP) to replace the 2018 Incentive Plan, authorizing up to 4,825,000 shares. The new plan includes minimum vesting requirements for 95% of awards (at least 3 years for non-performance, 12 months for performance) and double-trigger vesting on change of control. | Upon shareholder approval (May 5, 2026) | Modernizes the equity compensation framework, aligns with evolving governance standards, and aims to attract and retain key talent while protecting shareholder interests through prudent share usage and vesting conditions. |
| Director Qualification Standards | The Board determined that Mr. Abraham Ceesay does not qualify as an independent director due to his serving as an executive officer of a Company client. | NA | Maintains strict independence standards for the majority of the board, ensuring objective oversight, though one director's classification as non-independent due to client ties is noted. |
Legal Proceedings
- The company incurred "certain legal costs in our Safety Assessment business related to U.S. government investigations into the NHP supply chain" in fiscal year 2025.
- A $27 million inventory charge was incurred within the Discovery Safety Assessment (DSA) segment in 2024 to write down inventory associated with the Cambodia-sourced non-human primate matter from February 16, 2023, with reductions to this charge in 2025 due to case resolution.
Related Party Transactions
- None reported since the beginning of fiscal year 2025.
Stakeholder Impact
- Shareholders: Will vote on key governance matters, including director elections, executive compensation, and a new long-term incentive plan. The new $1.0 billion stock repurchase authorization and the company's commitment to returning value are positive. However, the GAAP loss and decreased revenue in 2025 may impact investor sentiment.
- Employees: The proposed 2026 Long-Term Incentive Plan is designed to attract, retain, and motivate key employees. Changes in executive compensation structure (eliminating options for named executives) aim to strengthen alignment and retention. Restructuring initiatives may impact staffing levels.
- Customers (Biopharmaceutical Clients): The company's strategic focus on enhancing scientific capabilities, digital platforms (Apollo), and operational efficiencies aims to provide more flexible, efficient, and high-science outsourcing solutions, improving client service and accelerating drug development timelines.
- Management: A significant leadership transition is underway with a new CEO and Board Chair, aiming for long-term continuity and strategic alignment. Executive compensation is tied to performance, with a substantial portion at risk.
- Regulatory Authorities: The company's adherence to SEC rules, NYSE listing standards, and its clawback policy demonstrates commitment to regulatory compliance. Ongoing U.S. government investigations into the NHP supply chain highlight regulatory scrutiny in certain operational areas.
Next Steps
- Shareholders to vote on director elections, executive compensation, 2026 Long-Term Incentive Plan, and auditor ratification at the Annual Meeting on May 5, 2026.
- Birgit Girshick to assume the role of Chief Executive Officer, effective May 5, 2026.
- Martin W. Mackay to become Chair of the Board, effective May 5, 2026.
- Company to continue strategic initiatives including acquisitions, partnerships, internal investments, and divestments of non-core assets.
- Company to continue efforts in optimizing infrastructure, utilizing automation, and investing in digital enterprise.
- Company to continue global footprint optimization and restructuring initiatives.
- Company to continue commercial enhancements to promote client-centric focus and gain market share.
- Company to continue efforts to secure its supply chain and mitigate NHP supply challenges.
- Company to implement the new $1.0 billion stock repurchase authorization.
- Company to file a Registration Statement on Form S-8 with the SEC after shareholder approval of the 2026 Long-Term Incentive Plan.
- Compensation Committee to continue exploring ways to improve executive compensation programs.
Key Dates
| Date | Description |
|---|---|
| 1976 | James C. Foster joined Charles River Laboratories. |
| 1989 | James C. Foster became a director. |
| 1989 | Birgit Girshick joined Charles River Laboratories. |
| 1991 | James C. Foster was named President. |
| 1992 | James C. Foster was named Chief Executive Officer. |
| 1993 | Nancy C. Andrews was a biomedical research investigator of the Howard Hughes Medical Institute (until 2006). |
| 1999 | PricewaterhouseCoopers LLP began serving as the company's auditor. |
| 1999 | Craig B. Thompson was a Professor of Medicine and Cancer Biology at the University of Pennsylvania (until 2011). |
| 2000 | James C. Foster was named Chair of the Board. |
| 2003 | Nancy C. Andrews served as Dean for Basic Sciences and Graduate Studies and Professor of Pediatrics at Harvard University Medical School (until 2007). |
| 2004 | Birgit Girshick was promoted to General Manager of the Avian Vaccine Services business. |
| 2006 | Craig B. Thompson served as the Director of the Abramson Cancer Center at the University of Pennsylvania School of Medicine (until 2010). |
| 2007 | Nancy C. Andrews served as Professor of Pediatrics and Professor of Pharmacology & Cancer Biology at Duke University (until Dec 2021). |
| 2007 | Nancy C. Andrews served as Dean of the Duke University School of Medicine and Vice Chancellor for Academic Affairs at Duke University (until 2017). |
| 2009 | Birgit Girshick was named Executive Director, RMS Process Improvement. |
| 2009 | Craig B. Thompson served on the Board of Directors of Merck & Co. Inc. (until 2018). |
| 2010 | Birgit Girshick was promoted to Corporate Vice President, Global Biopharmaceutical Services. |
| 2010 | Martin W. Mackay served as President of R&D at AstraZeneca PLC (until Jan 2013). |
| 2010 | Craig B. Thompson served as President and Chief Executive Officer of Memorial Sloan-Kettering Cancer Center (until Sep 2022). |
| 2013 | Birgit Girshick was promoted to Corporate Senior Vice President, Research Models and Biologics Testing Solutions. |
| 2013 | Martin W. Mackay served as Global Head of Research & Development at Alexion Pharmaceuticals, Inc. (until Jun 2017). |
| 2014 | Reshema Kemps-Polanco held leadership positions at Johnson & Johnson (until 2021). |
| 2016 | Birgit Girshick led the integration of WIL Research into the Safety Assessment business. |
| 2016 | Birgit Girshick assumed the role of Corporate Senior Vice President, Global Discovery Services. |
| 2017 | Martin W. Mackay became a director. |
| 2018 | Birgit Girshick was appointed Corporate Executive Vice President, Global Discovery and Safety Assessment. |
| 2018 | Birgit Girshick took on responsibility for Biologics Solutions and Avian Vaccine Services business. |
| 2018 | Nancy C. Andrews became a member of the Scientific Advisory Boards of Dyne Therapeutics. |
| 2019 | Virginia M. Wilson became a director. |
| 2020 | Nancy C. Andrews became a director. |
| 2020 | Steven Barg joined Elliott Investment Management L.P. |
| 2020 | George Llado, Sr. became a director. |
| 2021 | Birgit Girshick was promoted to Chief Operating Officer. |
| 2021 | Reshema Kemps-Polanco returned to Novartis as EVP & US Head, Novartis Oncology. |
| 2021 | Nancy C. Andrews became Executive Vice President and Chief Scientific Officer at Boston Children's Hospital (Dec 2021). |
| 2021 | Greenhouse Gas (GHG) emission reduction goals approved by Science Based Targets Initiative (SBTi). |
| 2022 | Craig B. Thompson became a director. |
| 2023 | Company launched Apollo, a cloud-based platform. |
| 2023 | Birgit Girshick assumed general oversight of Corporate Sales and Marketing and Corporate and External Affairs. |
| 2023 | Company acquired a 90% controlling interest in Noveprim Group. |
| 2023 | Shareholders approved annual advisory vote on executive compensation. |
| 2024 | Reshema Kemps-Polanco became a board member. |
| 2024 | Global Policy on Safety & Sustainability updated. |
| 2025 | Steven Barg became a director. |
| 2025 | Abraham Ceesay became a director. |
| 2025 | Mark Enyedy became a director. |
| 2025 | Paul Graves became a director. |
| 2025 | NAMS Committee created, combining Responsible Animal Use Committee and Science and Technology Committee (May 2025). |
| 2025 | Company launched a project management program to identify and implement sustainable projects within operations. |
| 2025 | Company repurchased 2.1 million shares of common stock for $350.0 million. |
| 2025-02-11 | Compensation Committee decided to eliminate stock options for named executives for 2025 grants. |
| 2025-05-06 | Company entered into Cooperation Agreement with Elliott Investment Management L.P. |
| 2025-05-20 | Terms of Mr. Foster's employment agreement amended and restated. |
| 2025-05-20 | Terms of Mr. Massaro, Dr. Kochevar, Mr. Bertolini, and Mr. Wallman's directorships ended as they chose not to stand for re-election. |
| 2025-05-30 | Annual RSU and PSU awards granted to named executives. |
| 2025-09-12 | Ms. Flavia H. Pease informed the company of her intention to resign as Corporate Executive Vice President, Chief Financial Officer. |
| 2025-09-14 | Mr. Michael Knell appointed Interim Chief Financial Officer. |
| 2025-09-28 | Mr. Knell's salary increase effective date. |
| 2025-09-29 | Ms. Pease's resignation as CFO effective date. |
| 2025-10-01 | Mr. Knell's $10,000 monthly cash payment as interim CFO began. |
| 2025-10-29 | Board of Directors approved a new stock repurchase authorization of $1.0 billion. |
| 2025-11-01 | Date used to identify median employee for pay ratio disclosure. |
| 2025-11-06 | One-time RSU grant to Mr. Knell as interim CFO. |
| 2025-12-26 | Last trading day of fiscal year 2025. |
| 2025-12-27 | Fiscal year 2025 ended. |
| 2026-01-08 | Board announced leadership transition plan for Mr. Foster and Ms. Girshick. |
| 2026-01 | Nancy C. Andrews became a member of the Scientific Advisory Boards of Cajal Therapeutics. |
| 2026-01 | Compensation Committee finalized payout for 2023 PSUs. |
| 2026-01 | Company acquired certain assets of K.F. (Cambodia) Ltd. |
| 2026-02 | 2025 EICP cash bonuses paid. |
| 2026-03-11 | Board of Directors adopted the 2026 Long-Term Incentive Plan, subject to shareholder approval. |
| 2026-03-16 | Record date for shareholders entitled to notice and vote at the Annual Meeting. |
| 2026-03-31 | Proxy Statement and Annual Report to Shareholders mailed. |
| 2026-04-06 | Mr. Knell's tenure as interim Chief Financial Officer expected to conclude. |
| 2026-05-04 | Deadline for electronic votes (11:59 p.m., Eastern Time). |
| 2026-05-05 | Annual Meeting of Shareholders to be held. |
| 2026-05-05 | Effective date for James C. Foster to step down as CEO and Chair, and Birgit Girshick to be appointed CEO. |
| 2026-05-05 | Effective date for Martin W. Mackay to become Chair of the Board. |
| 2026-05 | Expected date for annual equity grants to management-level employees, including Ms. Girshick's initial equity grant as CEO. |
| 2026-05 | Beginning of increased annual base cash fee for non-employee directors ($75,000) and additional annual fee for Chair of the Board ($175,000). |
| 2026-11-01 | Earliest date for shareholder proxy access nominations for 2027 Annual Meeting. |
| 2026-12-01 | Latest date for shareholder proposals for inclusion in 2027 proxy statement. |
| 2026-12-01 | Latest date for shareholder proxy access nominations for 2027 Annual Meeting. |
| 2026-12-26 | Fiscal year 2026 ending date. |
| 2027-01-05 | Earliest date for shareholder advance notice nominations for 2027 Annual Meeting. |
| 2027-02-04 | Latest date for shareholder advance notice nominations for 2027 Annual Meeting. |
| 2027-03-08 | Latest date for shareholder director nominations under Rule 14a-19 for 2027 Annual Meeting. |
| 2028-03-20 | Expiration of the 2018 Incentive Plan if the 2026 Plan is not approved. |
| 2030 | Company committed to a 50% reduction in GHG emissions (Scope 1 and 2) from global facilities by 2030. |
| 2030 | Company committed to a 15% reduction in value chain GHG emissions (Scope 3) by 2030. |
| 2036-03-11 | Expiration date for granting awards under the 2026 Long-Term Incentive Plan. |
Recommendation
holdWhile Charles River Laboratories demonstrates strong corporate governance, a clear leadership succession plan, and strategic initiatives to enhance its portfolio and operational efficiency, the significant GAAP loss in fiscal year 2025 due to non-cash impairments and the slight decline in revenue and non-GAAP EPS warrant a cautious 'hold' recommendation. The market environment remains challenging, and while the company is taking steps to adapt, the immediate financial performance indicates headwinds. Investors should monitor the execution of strategic divestitures, the impact of the new leadership, and the effectiveness of the 2026 Long-Term Incentive Plan in driving future growth and shareholder value before considering a stronger position.
Keywords
Charles River Laboratories, CRL, SEC Filing, Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Long-Term Incentive Plan, Director Election, Biopharmaceutical, Contract Research Organization, CRO, Drug Development, Risk Management, Shareholder Vote, Leadership Transition, Stock Repurchase, Financial Performance, ESG, PricewaterhouseCoopers
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.